A phase II study of the multitargeted kinase inhibitor lenvatinib in patients with advanced BRAF wild-type melanoma

被引：0
|
作者：
O'Day, Steven
Gonzalez, Rene
Kim, Kevin
Chmielowski, Bartosz
Kefford, Richard
Long, Georgina
Loquai, Carmen
Cowey, Charles Lance
Hauschild, Axel
Hainsworth, John D.
Hersey, Peter
Boyle, Frances
Evans, T. R. Jeffry
Hamid, Omid
Meneses, Nicole
Andresen, Corina
Ren, Min
O'Brien, James P.
Flaherty, Keith
机构：
[1] Beverly Hills Canc Ctr, Beverly Hills, CA USA
[2] UCHSC, Aurora, CO USA
[3] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[4] Univ Calif Los Angeles, Los Angeles, CA USA
[5] Westmead Hosp, Westmead, NSW 2145, Australia
[6] Univ Sydney, Sydney, NSW 2006, Australia
[7] Johannes Gutenberg Univ Mainz, Univ Med, D-55122 Mainz, Germany
[8] Texas Oncol, Dallas, TX USA
[9] Univ Klinikum Schleswig Holstein, Kiel, Germany
[10] Sarah Cannon Res Inst, Nashville, TN USA
[11] Tennessee Oncol, Nashville, TN USA
[12] Calvary Mater Newcastle, Waratah, Australia
[13] Melanoma Inst Australia, Sydney, NSW, Australia
[14] Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland
[15] Angeles Clin & Res Inst, Los Angeles, CA USA
[16] Eisai Inc, Woodcliff Lake, NJ USA
[17] Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9026
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Phase Ib/II Study of Cetuximab plus Pembrolizumab in Patients with Advanced RAS Wild-Type Colorectal Cancer
    Fountzilas, Christos
    Bajor, David L.
    Mukherjee, Sarbajit
    Saltzman, Joel
    Witkiewicz, Agnieszka K.
    Maguire, Orla
    Minderman, Hans
    Nambiar, Ram
    Rosenheck, Hanna R.
    Knudsen, Erik S.
    Muhitch, Jason B.
    Abrams, Scott, I
    Wang, Chong
    Hutson, Alan D.
    Attwood, Kristopher
    Hicks, Karen A.
    Jurcevic, Jennifer A.
    Kalinski, Pawel
    Iyer, Renuka
    Boland, Patrick M.
    CLINICAL CANCER RESEARCH, 2021, 27 (24) : 6726 - 6736
  • [32] Sequential treatment approaches in the management of BRAF wild-type advanced melanoma: a cost-effectiveness analysis
    Tarhini, Ahmad
    Benedict, Agnes
    McDermott, David
    Rao, Sumati
    Ambavane, Apoorva
    Gupte-Singh, Komal
    Sabater, Javier
    Ritchings, Corey
    Aponte-Ribero, Valerie
    Regan, Meredith M.
    Atkins, Michael
    IMMUNOTHERAPY, 2018, 10 (14) : 1241 - 1252
  • [33] Real-life use of trametinib after immunotherapy failure in BRAF wild-type advanced melanoma
    Pigne, Tristan
    Levy, Marie
    Ducharme, Oceane
    Dutriaux, Caroline
    Gerard, Emilie
    Pham-Ledard, Anne
    Beylot-Barry, Marie
    Prey, Sorilla
    MELANOMA RESEARCH, 2023, 33 (03) : 252 - 256
  • [34] A COST EFFECTIVENESS ANALYSIS OF NIVOLUMAB COMPARED TO IPILIMUMAB FOR THE TREATMENT OF BRAF WILD-TYPE ADVANCED MELANOMA IN AUSTRALIA
    Bohensky, M.
    Pasupathi, K.
    Gorelik, A.
    Kim, H.
    Harrison, J. P.
    Liew, D.
    VALUE IN HEALTH, 2015, 18 (07) : A340 - A340
  • [35] Successful combined Immune Checkpoint Blockade for locally advanced BRAF Wild-type Melanoma of the elderly Patient
    Spaenkuch, I
    Pfeiffer, C.
    Tietze, J.
    Welzel, J.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2019, 17 : 153 - 154
  • [36] A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours
    Boss, D. S.
    Glen, H.
    Beijnen, J. H.
    Keesen, M.
    Morrison, R.
    Tait, B.
    Copalu, W.
    Mazur, A.
    Wanders, J.
    O'Brien, J. P.
    Schellens, J. H. M.
    Evans, T. R. J.
    BRITISH JOURNAL OF CANCER, 2012, 106 (10) : 1598 - 1604
  • [37] Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma A Pooled Analysis of 4 Clinical Trials
    Larkin, James
    Lao, Christopher D.
    Urba, Walter J.
    McDermott, David F.
    Horak, Christine
    Jiang, Joel
    Wolchok, Jedd D.
    JAMA ONCOLOGY, 2015, 1 (04) : 433 - 440
  • [38] Assessment of clinical activity of E7080, a multitargeted kinase inhibitor, in patients with advanced melanoma treated in two phase I trials
    Hong, D. S.
    Boss, D. S.
    Glen, H.
    Mink, J.
    Ren, M.
    Andresen, C.
    O'Brien, J. P.
    Kurzrock, R.
    Schellens, J. H. M.
    Nemunaitis, J. J.
    Evans, T. R. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [39] Is a Single BRAF Wild-Type Test Sufficient to Exclude Melanoma Patients from Vemurafenib Therapy?
    Saint-Jean, Melanie
    Quereux, Gaelle
    Jean-Michel Nguyen
    Peuvrel, Lucie
    Brocard, Anabelle
    Vallee, Audrey
    Knol, Anne-Chantal
    Khammari, Amir
    Denis, Marc G.
    Dreno, Brigitte
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2014, 134 (05) : 1468 - 1470
  • [40] BRAF/MEK inhibitor rechallenge in advanced melanoma patients
    Van Not, Olivier J.
    van den Eertwegh, Alfons J. M.
    Haanen, John B.
    van Rijn, Rozemarijn S.
    Aarts, Maureen J. B.
    van den Berkmortel, Franchette W. P. J.
    Blank, Christian U.
    Boers-Sonderen, Marye J.
    de Groot, Jan Willem W. B.
    Hospers, Geke A. P.
    Kapiteijn, Ellen
    Bloem, Manja
    Piersma, Djura
    Stevense-den Boer, Marion
    Verheijden, Rik J.
    van der Veldt, Astrid A. M.
    Wouters, Michel W. J. M.
    Blokx, Willeke A. M.
    Suijkerbuijk, Karijn P. M.
    CANCER, 2024, 130 (09) : 1673 - 1683
12345